Overview

An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability

Status:
Completed
Trial end date:
2020-06-26
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix.
Phase:
Phase 1
Details
Lead Sponsor:
scPharmaceuticals, Inc.
Collaborators:
Clinical Trial Data Services, Inc.
CSSi Life Sciences
Treatments:
Furosemide